Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

ALX Oncology

Contributing Author

Recent Articles by ALX Oncology

Sep-02
ALX Oncology to Present at Upcoming Investor Conferences in September ALXO +5.05% GlobeNewswire
Aug-06
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update ALXO +9.90% GlobeNewswire
Jun-30
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules ALXO -5.91% GlobeNewswire
Jun-30
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel ALXO -5.91% GlobeNewswire
Jun-01
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York ALXO -5.26% GlobeNewswire
May-08
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update ALXO +11.23% GlobeNewswire
May-07
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression ALXO -10.53% GlobeNewswire
Apr-30
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 ALXO +7.59% GlobeNewswire
Apr-17
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules ALXO GlobeNewswire
Apr-13
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer ALXO GlobeNewswire
Feb-27
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update ALXO -10.21% GlobeNewswire
Feb-19
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 ALXO +12.07% GlobeNewswire
Feb-19
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 ALXO +12.07% GlobeNewswire
Jan-30
ALX Oncology Announces Pricing of Underwritten Offering ALXO +10.83% GlobeNewswire
Jan-30
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer ALXO +10.83% GlobeNewswire
Jan-08
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference ALXO +5.08% ALXO +8.87% GlobeNewswire
Jan-08
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 ALXO +5.08% GlobeNewswire
Dec-07
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting ALXO GlobeNewswire
Nov-18
ALX Oncology to Present at Upcoming Investor Conferences ALXO ALXO -9.82% GlobeNewswire
Nov-07
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update ALXO +16.95% GlobeNewswire
Oct-30
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting ALXO GlobeNewswire
Oct-23
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference ALXO +8.70% GlobeNewswire
Oct-03
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting ALXO +14.14% GlobeNewswire
Sep-12
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer ALXO -10.17% GlobeNewswire
Aug-29
ALX Oncology to Participate in Upcoming Investor Conferences in September ALXO ALXO -11.97% GlobeNewswire
Aug-19
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors ALXO -8.37% GlobeNewswire
Aug-12
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update ALXO ALXO +7.40% GlobeNewswire
Aug-05
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 ALXO +12.68% GlobeNewswire
May-30
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference ALXO GlobeNewswire
May-20
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event ALXO GlobeNewswire
May-13
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 ALXO +10.52% GlobeNewswire
May-08
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update ALXO GlobeNewswire
May-02
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 ALXO GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)